Tumor necrosis factor-alpha and Tumor necrosis factor receptor 1 (TNF-alpha/TNFR1)

Tumor necrosis factor-alpha (TNF-alpha) is a potent pleiotropic cytokine that serves as a central regulator of inflammation and immune homeostasis. It exerts its biological effects primarily by binding to Tumor necrosis factor receptor 1 (TNFR1), a ubiquitously expressed cell surface receptor characterized by an intracellular death domain. Activation of the TNF-alpha/TNFR1 pathway triggers complex signaling cascades, including the NF-kappaB and MAPK pathways, which promote the expression of pro-inflammatory genes, as well as apoptotic or necroptotic cell death pathways depending on the cellular context. Dysregulation and overproduction of TNF-alpha are major drivers in the pathogenesis of numerous chronic inflammatory and autoimmune diseases, such as rheumatoid arthritis, psoriasis, and inflammatory bowel disease. Therapeutic strategies targeting this pathway involve the use of monoclonal antibodies or soluble receptor fusion proteins that neutralize TNF-alpha, thereby preventing its interaction with TNFR1 and dampening the systemic inflammatory response. While highly effective, these therapies are associated with significant safety concerns, including an increased risk of serious opportunistic infections and potential malignancy due to their broad immunosuppressive effects.

Other names

TNFTNFATNFSF2CachectinTumor necrosis factor ligand superfamily member 2TNFRSF1ACD120ap55p60TNF-R1

Neutralization of soluble and transmembrane TNF-alpha; Inhibition of TNF-alpha binding to TNFR1; Induction of antibody-dependent cellular cytotoxicity (ADCC); Reverse signaling through transmembrane TNF-alpha